Skip to content
MARKETS / NASDAQ / BLFS
NASDAQ · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · LARGE CAP

Biolife Solutions Inc. BLFS

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$96.2M
▲ 28.9% YoY
$-4.6M
$10.6M
▲ 104.4% YoY
In brief

What this company does

BioLife Solutions, Inc. is a life sciences company that develops, manufactures, and markets bioproduction products and services which are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. It currently operates as one bioproduction products and services business which supports several steps in the biologic material manufacturing and delivery process. Its bioproduction products and services are comprised of one revenue line that contains three main offerings: cell processing and other products, including biopreservation media, human platelet lysate media, cryogenic and ultralow temperature containers, and automated cell-processing fill machines; and automated thawing devices. It maintains and operates two independent cGMP clean room production suites for manufacturing sterile biopreservation media products in Bothell, Washington. It also maintains and operates one cGMP clean room production suite for manufacturing hPL media in Indianapolis, Indiana. As of December 31, 2025, it had 155 full-time team members and no part-time team members. The company was incorporated in Delaware in 1987 under the name Trans Time Medical Products, Inc. Following a later merger with its wholly owned subsidiary, it changed its name to BioLife Solutions, Inc.

Written from the business description in BIOLIFE SOLUTIONS INC's annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth
USD 96.2M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 96.2 · Net income -4.6
40M80M-50M-100M201020122014201620182020202220242025
Compound annual growth
+8.1%
+14.9%
+31.0%
+29.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +14.9% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−5 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -17.3% · Net -4.8%
-50%-100%-150%201020122014201620182020202220242025
ROE
FY2025 · ROE -1.3%
-500%201020122014201620182020202220242025

Each USD of equity lost 1 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 10.6
4M8M-8M-16M201020122014201620182020202220242025

Total assetsUSD 405.9M
EquityUSD 371.9M
CashUSD 33.0M
Gross debtUSD 5.0M
Net debtUSD -28.0M
Current ratio5.94×

The company holds more cash than debt.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.10.10.10.10.10.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.00.0−0.00.0−0.0−0.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.0−0.0−0.0−0.0−0.0−0.0−0.0·0.00.00.00.00.00.0··
Net income $B−0.0−0.0−0.1−0.1−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B0.00.0−0.0−0.0−0.00.00.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.10−0.44−1.55−3.25−0.23−0.06−0.09−1.56−0.21−0.54−0.35−0.31−0.22−0.33−0.03−0.03
Dividend / sh $················
Payout %················
ROE %−1.3−5.9−19.4−33.2−2.61.6−5.7−980.6·−117.8−37.5−968.0····
Shares out B0.050.050.000.040.040.030.020.020.010.010.010.010.010.000.070.07

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 75 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 19 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2010

Share this section

Download image